![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 39, 27474-27480, September 24, 1999
From the Department of Pathology, State University of New York, Stony Brook, New York 11794
| |
ABSTRACT |
|---|
|
|
|---|
The Mdm2 oncoprotein mediates p53 degradation at
cytoplasmic proteasomes and is the principal regulator for maintaining
low, often undetectable levels of p53 in unstressed cells. However, a
subset of human tumors including neuroblastoma constitutively harbor
high levels of wild type p53 protein localized to the cytoplasm. Here
we show that the abnormal p53 accumulation in such cells is due to a
profound resistance to Mdm2-mediated degradation. Overexpression of
Mdm2 in neuroblastoma (NB)1
cell lines failed to decrease the high steady state levels of endogenous p53. Moreover, exogenous p53, when introduced into these
cells, was also resistant to Mdm2-directed degradation. This resistance
is not due to a lack of Mdm2 expression in NB cells or a lack of
p53-Mdm2 interaction, nor is it due to a deficiency in the
ubiquitination state of p53 or proteasome dysfunction. Instead,
Mdm2-resistant p53 from NB cells is associated with covalent modification of p53 and masking of the modification-sensitive PAb 421 epitope. This system provides evidence for an important level of
regulation of Mdm2-directed p53 destruction in vivo that is
linked to p53 modification.
Controlling the stability of the p53 tumor suppressor protein is
crucial for an effective cellular stress response when needed and for
keeping this dangerous molecule in check when not needed. p53 levels
are largely regulated by interaction with Mdm2, a negative regulator of
p53 and the product of a p53-inducible gene (1, 2). Posttranslational
modification has been associated with stabilizing p53 protein during
cellular stress responses. DNA damage induces specific phosphorylations
on N-terminal serine residues of p53 in vivo, possibly
catalyzed by various stress kinases, thereby preventing Mdm2 binding,
which in turn alleviates transcriptional inhibition and stabilizes p53
by inhibiting its degradation (3, 4). As a consequence, p53 half-life
prolongs from minutes to hours (5). Conversely, tight regulation of p53
is critical for normal growth of unstressed cells, in which p53 is a
short lived protein (half-life, 20-30 min) that is maintained at low,
often undetectable levels through continuous degradation mainly
directed by Mdm2. Hence, Mdm2 is largely responsible for the high p53
turnover in undamaged cells (6). Mdm2-mediated p53 degradation occurs
through a ubiquitin-dependent pathway on cytoplasmic 26S
proteasomes (7, 8). Mdm2 functions as a p53-specific E3 ubiquitin
ligase in vitro (9) and this ubiquitination probably takes
place in the nucleus on the large p300/CBP protein, serving as a
scaffolding (10).
Recent studies of p53 turnover using overexpression assays with p53 and
Mdm2 mutants elucidated some structural requirements for
Mdm2-dependent destruction of p53. Together, these studies reveal the importance of several regions on both proteins, particularly on the N and C termini, the precise contributions of which, however, are not all understood. A basic but insufficient requirement is a
direct interaction between the two proteins through their N termini. An
Mdm2-binding site mutant of p53 (conserved box I) is resistant to
degradation by Mdm2 (1, 2). Crystallographic analysis of the
interacting domains has shown a tight key-lock configuration (11), with
p53 domain amino acids 17-27 fitting deeply into a hydrophobic cleft
of Mdm2. Also, Mdm2 shuttles between the nucleus and the cytoplasm, and
Mdm2-directed degradation of p53 depends on a functional nuclear export
signal of Mdm2 (12-14). Lastly, the C-terminal RING finger domain of
Mdm2 is somehow required, because deletion or mutations in this region
act as dominant negative mutants and protect p53 from degradation by
endogenous Mdm2 (15). In addition, the p14ARF protein, which binds to
the C-terminal region of Mdm2, can inhibit Mdm2-mediated p53
degradation without disrupting the p53-Mdm2 complex (16-18), possibly
due to inhibiting the E3 ubiquitin ligase activity of Mdm2 (19). To
date, known requirements on p53 include p53 tetramerization, which,
although not absolutely required, enhances degradability, possibly via improved Mdm2 binding. A monomeric p53 mutant lost sensitivity to
degradation by Mdm2 (20). Also, the extreme C terminus of p53 (amino
acids 363-393) is required, because p53 mutants with deletions of this
region show constitutive Mdm2 resistance in unstressed cells due to an
unknown mechanism (20).
Certain human tumors, including neuroblastoma (21), breast cancer
(22-24), colon cancer (25-27), and retinoblastoma (28), as well as
normal mouse embryonic stem cells (29), constitutively accumulate high
levels of wild type p53 protein in their cytoplasm in the absence of
stress. This is due to a dramatic increase in p53 half-life (>8 h in
unstressed neuroblastoma cells) (30), thereby stabilizing the protein.
Thus, this phenotype is due to inefficient degradation of p53 rather
than to increased synthesis. The cytoplasmic p53 accumulation is also
the hallmark of a concomitant defect in p53 function in response to
genotoxic stress (31, 32, 29) and, in fact, prompted its original
observation (21, 22). We recently showed that this seemingly static
sequestration of p53 is in fact not due to a blocked nuclear entry but
due to a dynamic imbalance characterized by hyperactive p53 export from the nucleus (33). Functional inactivation of p53 in response to stress
is therefore to a large degree due to an inefficiency in nuclear
retention of p53 (31, 32, 29). Using human neuroblastoma cell lines, we
show here that the aberrant constitutive p53 accumulation in these
cells is due to resistance to Mdm2-mediated degradation. This
resistance is observed despite normal levels of Mdm2 protein, p53-Mdm2
complexes, and p53 ubiquitination. Instead, stabilization correlates
with covalent modification of p53, characterized by an acidic shift in
the charge isoform profile of p53 and masking of its
modification-sensitive 421 epitope. This system provides evidence for a
novel level of in vivo regulation of p53 destruction by Mdm2
linked to posttranslational p53 modification.
Cell Culture and Reagents--
The following cell lines were of
human origin: the neuroblastoma lines LAN-5, SK-N-SH, IMR 32, CHP 134, and SK-N-AS exhibit constitutive cytoplasmic accumulation of wild type
p53 protein. The osteosarcoma line SaOs-2 is homozygously deleted for
p53; the neuroepithelioma line CHP 100 is deficient for p53 expression due to aberrant mRNA; the chronic myelogenous leukemia line ML-1, the fibrosarcoma line HT 1080, and the diploid immortal fibroblast line
IMR 90 all contain low levels of functional wild type p53; and the
colon carcinoma line RKO contains mildly elevated levels of functional
wild type p53. The breast cancer lines MDA 231 and MDA 468 harbor a
R280K and R273K mutation, respectively. Mouse DM cells harbor an
amplification of the Mdm2 gene (34). All cells were cultured in
Dulbecco's modified Eagle's medium/10% fetal calf serum. For p53
ubiquitination, proteasome inhibitor MG101 (50 mM) (Sigma)
was added to the culture medium for 5 h before lysates were
prepared. Baculoviral human wild type p53 protein was purified on a
MonoQ column and appeared as a single band on silver gels. Various
normal human tissues were collected at University Hospital Stony Brook
during surgical resections and immediately snap frozen after
harvesting. Undifferentiated neuroblastoma tumors were previously
described and collected in the same way (21).
Plasmids--
Human Mdm2 expression plasmids, all pCMV
BamNeo-based (35), were kindly provided by Arnold J. Levine. HDM2
encodes wild type Mdm2 (36), G58A encodes a contact mutant of Mdm2 that
abolishes its interaction with p53 (8), and mutant nuclear export
signal encodes an export mutant of Mdm2, leading to its nuclear
retention due to the change of two critical hydrophobic residues within the nuclear export signal (L205A and I208A) (12). N-terminally FLAG-tagged human wild type p53 (Fwtp53) was generated by polymerase chain reaction using pC53-SN3 (35) as template. The sense primer contained a BamHI site upstream of the sequence encoding the
FLAG octapeptide (5'-AG CAG TTG GGA TCC ATG GAC TAC AAG GAC GAC GAT GAC
AAG ATG GAG GAG CCG CAG TCA GAT CCT AGC G-3'), and the antisense primer
also contained a BamHI site (5'-TTA TTC GGA TCC AGA ATG TCA
GTC TGA GTC AGG CCC-3'). The polymerase chain reaction product was
cloned into pCMV BamNeo. The pFwtp53 plasmid was also used to construct
the p53 C-terminal plasmids F305-360 and F320-360 by polymerase chain
reaction overlap extension technique as described (33). The plasmid
pcDNA3-Myc-ARF expressing human wild type p14ARF fused to a Myc tag
was described previously (37). Green fluorescent protein (GFP)
expression plasmid (CLONTECH) was co-transfected in
transient transfections to normalize relative transfection efficiency.
Transfections--
Cells were plated in 60-mm dishes and grown
overnight to 80% confluence. Two mg of Mdm2 wild type or
mutant-encoding plasmid was co-transfected with 0.4 mg of GFP-encoding
plasmid and 0.6 mg of wild type p53-encoding plasmid or CMV BamNeo
empty vector using the LipofectAMINE Plus reagent (Life Technologies,
Inc.) as recommended by the manufacturer. For transient transfections, cells were collected after 24 h, whereas stable transformants were
selected by growth for 21 days in medium containing 0.5 mg/ml G418
(Life Technologies, Inc.), ring cloned, and expanded into single cell
clones. For Myc-p14ARF expression, 2 mg of plasmid was used.
Antibodies, Western Analysis, and Immunoprecipitation--
Cell
lysates from unstressed cells were prepared as described (31),
subjected to 8% SDS-polyacrylamide gel electrophoresis, and
transferred to nylon membranes. Immunoblots were visualized by ECL
(Pierce). Cell lysates (1 mg of total protein) were immunoprecipitated with 1.5 µg of the indicated antibody, incubated with 30 µl of protein G-agarose beads (Life Technologies, Inc.), washed five times in
radioimmune precipitation buffer (50 mM Tris, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 1% sodium
deoxycholate, pH 7.4) and visualized as described (31). Antibodies to
p53 were monoclonals PAb 421, 1801, and DO-1 (Oncogene Science), which
recognize epitopes amino acids 372-382 (421), 46-55 (1801), and
20-25 (DO1). CM-1 is a polyclonal rabbit antibody raised against
bacterial recombinant human wild type p53 (Vector). FLAG-tagged p53
constructs were detected with M2 (Eastman Kodak Co.). Mdm2 was detected
with monoclonal IF2 (Oncogene Science). Other antibodies used were
specific for vimentin (BioGenex), GFP (CLONTECH),
Myc (NeoMarker), IkBa (Santa Cruz), actin (Sigma), mouse IgG (Sigma),
and Lamin A (Chemicon).
Immune-isoelectric Focusing--
Crude cell lysates (2-20 mg),
prepared by sonication without ionic detergents and low salt (37), were
mixed with equal volume of 2× sample buffer (4.8 g urea, 120 ml each
of ampholytes pH 4-6 and 5-7 (Bio-Lyte, Bio-Rad), 1 ml of 20% Triton
X-100, 100 ml of 2-mercaptoethanol, 1 mg of bromphenol blue in 10 ml of
H2O) 5 min before loading. Loaded lysates and pH markers
(Bio-Rad) were overlaid with 1% mixed ampholytes and 5% sucrose to
protect proteins from the harsh pH conditions of the upper chamber.
Proteins were resolved along a gradient of pH 7-4 on one-dimensional
slab mini gels using polyacrylamide containing 8 M urea and
120 ml each of ampholyte pH 4-6 and pH 5-7 as described (38). The
upper chamber buffer (500 ml of catholyte, 20 mM sodium
hydroxide) and lower chamber buffer (500 ml of anolyte, 10 mM phosphoric acid) were prepared fresh and degassed, and
gels were run at 150 V for 30 min followed by 200 V for 3 h. Gels
were transferred to nylon membranes and p53 was detected by
immunoblotting with DO-1. In parallel, equal aliquots were run on 8%
SDS-polyacrylamide gel electrophoresis gels followed by DO-1
immunoblotting to verify p53 loading.
Immunofluorescence--
Subconfluent cells in P100 dishes were
refed 4 h prior to calcium phosphate-mediated transfection with 20 mg each of p53 C-terminal peptide or empty vector DNA constructs. After
overnight incubation, cells were aliquoted into polylysine-coated
chamber culture slides (Becton Dickinson) and grown for an additional
24 h. Cells were immunostained as described (33) and examined with
a Nikon scanning laser microscope. Expression of constructs was
verified by FLAG antibodies and was reproducible with transfection
efficiency over 50% (data not shown).
No Deficiency of Endogenous Mdm2 Protein in Neuroblastoma
Cells--
To exclude the possibility that the constitutively high
levels of wild type p53 protein in neuroblastoma (NB) cells are due to
a lack of expression of its destabilizer Mdm2, we compared a panel of
NB cells (SK-N-SH, LAN-5, IMR 32, CHP 134 and SK-N-AS) with a broad
range of other human cell lines (Fig.
1A and data not shown). These
made up four different types of p53 steady state levels, including
p53-deficient cells (SaOs-2 and CHP 100), low levels of functional p53
(HT 1080, IMR 90, and ML-1), mildly elevated levels of functional p53
(RKO), and markedly increased levels of mutant p53 due to a failure to
induce Mdm2 (MDA 231 and 468). Fig. 1A shows that steady
state levels of Mdm2 protein in NB cells are comparable to Mdm2 levels
in all other cell lines analyzed, with some variations in expression in
both categories. The only exception was an undetectably low Mdm2 level
in ML-1 cells (not shown) for reasons that are not clear.
Mdm2 Interacts with p53 in NB Cells--
A second possibility that
could explain the abnormal stability of p53 would be a lack of
interaction between p53 and Mdm2. To test this, we performed
co-immunoprecipitation assays from LAN-5 cells with an Mdm2-specific
antibody. Fig. 1B shows the presence of p53-Mdm2 complexes
indicating their interaction in vivo (lanes
SaOs-2 and RKO). Moreover, the amount of complexed p53
in LAN-5 cells is similar to the amount in IMR 90 control cells
(compare lanes RKO and HT1080). IMR 90 fibroblasts contain low levels of functional p53, indicating
sensitivity to Mdm2-directed degradation. These data demonstrate that
the abnormal p53 stability in NB cells is not due to a lack of p53-Mdm2
interaction. To further demonstrate that Mdm2 function is normal in NB
cells, we tested its ability to enter the physiologically important
interaction with p14ARF. Fig. 1C shows readily demonstrable
in vivo complexes between Mdm2 and p14ARF,
co-immunoprecipitated from a stably expressing Mdm2 NB cell line (clone
HDM2-2 of Fig. 2D) and
transiently transfected with Myc-tagged p14ARF.
p53 from NB Cells Is Properly Ubiquitinated--
Next we
examined whether p53 ubiquitination in NB cells is deficient,
because poor ubiquitination of p53 could lead to its stabilization.
Also, Mdm2 is a p53-specific E3 ubiquitin ligase in vitro.
LAN-5 cells and ML-1 control cells, which contain low levels of p53
indicating Mdm2 sensitivity, were treated with the proteasome inhibitor
MG101 for 5 h. p53 stabilized in both cases to a similar degree
(Fig. 1C, top panel, lowest band). More importantly, the
ladder of polyubiquitinated p53 species were similar in LAN-5 and ML-1
cells (Fig. 1D). This indicates that the in vivo
ubiquitination of p53, whether catalyzed by Mdm2 or some other E3
ligase, is functional in NB cells. Furthermore, these data also show
that NB cells do not have a global functional defect of their
proteasomes in processing ubiquitin-tagged proteins, because if this
were the case, ubiquitinated p53 should have been easily detected even in untreated cells. To further confirm this point, we asked whether the
processing of other proteasome-degraded proteins is normal in NB cells.
IkBa, the cytoplasmic inhibitor of NFkB, is a prototype protein
undergoing ubiquitin-mediated proteasome degradation (39). Fig.
1E shows that IkBa levels in NB cells are completely within the range of non-NB cells, indicating normal ubiquitin/proteasome processing in NB cells. Likewise, the same reasoning holds for Mdm2,
the levels of which in NB cells are within normal range, as shown above
(Fig. 1A), because Mdm2 itself is degraded via the ubiquitin
proteasome pathway (40).
p53 Is Resistant to Ectopic Mdm2 in NB Cells--
Although
endogenous Mdm2 in NB cells is sufficiently expressed and enters into
complexes with p53, it still left the possibility that Mdm2 had a
specific defect in directing p53 destruction. We therefore asked
whether the abnormal p53 stability could be overcome by overexpression
of functional ectopic Mdm2 protein. SaOs-2 control cells (p53 null),
transiently transfected with human wild type p53 (Fig. 2A, lane
2), showed a dramatic decrease in the endogenous p53 protein level
when co-transfected with wild type Mdm2 (lane 3) but not
with a p53-contact mutant of Mdm2 (G58A) (lane 4) as
described previously (1, 2, 12). In contrast, endogenous p53 protein
from LAN-5 (Fig. 2B) and SK-N-SH (Fig. 2C) was
completely resistant to degradation by forced expression of wild type
Mdm2 (Fig. 2, B and C, compare lanes 1 and 2 with lane 3), as well as to a nuclear
export mutant of Mdm2 (Fig. 2, B and C, lane 4)
and to a contact mutant of Mdm2 (Fig. 2, B and C, lane
5). To confirm this result, we generated a series of stable LAN-5
subclones that overexpress either vector alone, wild type Mdm2, or
contact mutant Mdm2. Of six wild type Mdm2 clones, all showed marked
resistance of p53 protein toward degradation (Fig. 2D,
compare lanes 2-5 with lanes 1, 6, and
7). Taken together, the data demonstrate that the abnormal
stability of p53 in NB cells is due to a profound resistance of the p53
protein to Mdm2-directed degradation and strongly suggest that the
principal defect lies in p53 and not in Mdm2.
To further support this conclusion, we asked whether exogenous human
wild type p53, when transfected into NB cells, was also resistant to
overexpressed Mdm2. Fig. 3 shows that
this is indeed the case. FLAG-tagged p53 (Fwtp53), when transiently
transfected into SK-N-SH and LAN-5 cells, is markedly resistant to
co-transfected wild type Mdm2, as it is resistant to contact mutant
Mdm2 (Fig. 3, compare lane 2 with lane 3 and
4). Together, these data show that the cellular environment
of NB cells causes the loss of sensitivity of the p53 protein toward
Mdm2-regulated turnover.
p53 Resistance to Mdm2-directed Degradation Is Associated with
Covalent Modification of p53--
Because the above results imply the
p53 protein itself in mediating its degradation defect, we investigated
whether wild type p53 protein from NB cells is constitutively subject
to altered posttranslational modification. Immune-isoelectric focusing
is a commonly used technique to characterize charge isoform profiles of
proteins. The high urea content used in the polyacrylamide gels (8 M) ensures the elimination of protein-protein interactions as another potential source of charge alterations. Cell lysates from
SK-N-SH and LAN-5 reveal an identical and specific shift in their p53
charge isoform profiles when compared with control p53 proteins derived
from cellular (MDA 231) or baculoviral sources (Fig.
4A, left panel). Both NB lines
show a shift in profile toward four prominent hyperacidic isoforms with
isoelectric points (pI) ranging from about 4.6 to 5.3 (20 µg
SH and 15 µg LAN-5). In contrast, both control p53
proteins exhibit inverted profiles (in relative proportions of the
individual species) that are dominated by more basic isoforms (2 µg MDA 231 and 60 ng bac p53). Purified baculoviral human wild type p53 (60 ng bac p53) has been shown to
exhibit identical posttranslational modifications to normal cellular
p53 (41). Mutant p53 from MDA 231 cells (2 µg MDA 231)
harbors a charge-neutral R280K exchange with loss of transactivating
function. MDA 231-derived p53 was chosen to show that p53 modification
is not a consequence of abnormal stability (which in this case is caused by the inability of mutant p53 to induce Mdm2). Both profiles consist of several tightly packed coalescing isoforms with pIs ranging
from 6 to 6.5, whereas the hyperacidic species so characteristic for NB
cells make up only a minor fraction. Conversely, the presence of the
basic species in NB cells was not consistent and, even when present,
presented only minor fractions. Supporting these data, on
SDS-polyacrylamide gel electrophoresis gels, neuroblastoma tumors and
NB cell lines exhibit two p53 bands after immunoprecipitation, which
are best seen with the polyclonal CM-1 antibody. Of these, the dominant
p53 species runs slower than the faster migrating single p53 species
present in normal human tissues and ML-1 cells (Fig. 4B,
compare lanes 5-7 with lanes 2-4, and data not
shown). The observed modifications are consistent with aberrant
phosphorylation and/or acetylation or other less common acidifying
modifications. rRNA moieties, covalently bound to a small subset of p53
polypeptides on ribosomes of normal cells in the G1 phase
of the cell cycle (42), are excluded because RNase A pretreatment of
the NB lysates does not change the isoform profile (data not
shown).
To further support the above findings, we probed NB cells with the p53
monoclonal antibody PAb 421, the ability of which to recognize its
epitope (amino acids 372-382) is modification-dependent (43-46). We had previously observed in immunofluorescence assays that
the 421 epitope in NB cells with cytoplasmically sequestered p53 is
completely masked (47). We then asked whether this masking was
dependent on cytoplasmic localization. To this end, we exploited the
effect of co-expressed p53 C-terminal polypeptides. These heterooligomerizing peptides specifically cause nuclear retention of
endogenous p53 in NB cells by disrupting hyperactive nuclear export,
probably through a combination of burying the intrinsic nuclear export
signal of p53 and interfering with its Mdm2-mediated export (33). This
effect is not due to a nonspecific titration of CRM1 export receptors,
because the localization of IkBa, a marker shuttling protein, is
unaffected by the C-terminal peptides (33). Transient transfections
with plasmids encoding the p53 polypeptides 305-360 and 320-360 show
that the 421 epitope remains largely unrecognizable despite nuclear
translocation of p53 (Fig. 4C, compare left and
right panels). Both PAb 1801 and PAb 421 antibodies are
specific for endogenous p53. Yet, whereas the 1801 antibody gives a
very strong signal, the 421 signal is barely detectable. This clearly
shows that the 421 epitope of NB p53 is masked constitutively and
independently of its subcellular localization. These data further
support covalent modification of p53 that includes the amino acid
372-382 region.
In this study we investigated the mechanism responsible for the
abnormal stability of wild type p53 protein, which constitutively accumulates in the cytoplasm of certain tumor cells and embryonic stem
cells. Concomitantly, cytoplasmic p53 accumulation in such cells is
also the hallmark of a defect in p53 function in response to genotoxic
stress and oncogenic transformation (31, 32, 29, 21, 22). We recently
showed that the seemingly static sequestration of p53 is due to
hyperactive export of p53 from the nucleus (33). Functional
inactivation of p53 in response to stress is therefore promoted by an
inefficiency in nuclear retention of p53 (31, 32, 29).
Using transient and stable overexpression assays in neuroblastoma
lines, we show here that the abnormal p53 stability of the cytoplasmic
sequestration phenotype is due to a profound resistance of p53 toward
Mdm2-mediated degradation. Moreover, we find that degradation-resistant
p53 is associated with an altered posttranslational modification
profile of the protein. This alteration is characterized by loss of
positively charged moieties and/or gain of negatively charged moieties
that include the amino acid 372-382 region. The fact that the p53
isoform profile in NB cells is inverted rather than completely novel
compared with p53 from other sources suggests that the same set of p53
modifying enzymes that are usually at work are active in NB cells but
that their relative activities are grossly altered. Although aberrant
phosphorylation is a possibility, our attempts to demonstrate it by
pretreating immunoprecipitated p53 with phosphatases have so far been
unconvincing. Future work will focus on the precise identification of
sites and types of modifications in NB p53. The observed 421 epitope
masking, independent of subcellular localization, is completely
consistent with modification of the amino acid 372-382 region or the
surrounding area. Furthermore, it could be structurally akin to the
effect seen with p53 delta 30 deletion, which renders the protein
Mdm2-resistant (20). Examples of complete 421 masking have been
described for epitope glycosylation in vivo (40), protein
kinase C-mediated phosphorylation of Ser-378 in vitro (44),
and partially for p300/CBP-mediated acetylation of Lys-373 and Lys-382
in vitro (46). In contrast to NB cells, however, select
phosphorylation or acetylation of recombinant p53 in vitro
correlates with activation of p53 sequence-specific DNA binding (44,
46). This reinforces the notion that it is the specific modification
profile of p53 in any given case that determines its effects on
stability and function of the protein.
A number of reasons support the conclusion that the cause for the
abnormal p53 stability in the cytoplasmic sequestration phenotype lies
in p53 itself. First, the loss of sensitivity is not due to a lack of
Mdm2 expression or its ability to interact with p53, nor is it due to a
defect in p53 ubiquitination or global proteasome dysfunction.
Moreover, endogenous Mdm2 from NB cells is unlikely to be functionally
defective in its p53-degrading activity because in that case active
ectopic Mdm2 would have overcome the block. Alternatively, could there
be a defect in the ability of Mdm2 to undergo nucleocytoplasmic
shuttling, which was shown to be required for p53 degradation? Again,
this is unlikely, given the hyperactive export of p53 that underlies
its cytoplasmic sequestration. Also, a nuclear export mutant of Mdm2
(mutant nuclear export signal) failed to further increase the total
cellular p53 levels in NB cells (Fig. 2, B and
C). The cytoplasmic accumulation of p53 also makes it
unlikely that an abnormality in p300/CBP, both of which are nuclear
proteins, play a role here. The multifunctional p300 protein was shown
to promote Mdm2-mediated p53 degradation in vivo through
preformed p300-Mdm2 complexes, possibly by enabling the ubiquitin
ligase activity of Mdm2 for p53 (10). In addition, we showed that p53
ubiquitination is not defective in NB cells.
During viral or cellular oncogene activation of the p53 pathway, p14ARF
promotes p53 stabilization by inactivating Mdm2 (see Ref. 48 for
review). As a possible mechanism, p14ARF inhibits the ubiquitin ligase
activity of Mdm2 for p53 in vitro (19). During the
attenuation of a p53 response, two antiparallel feed back loops connect
p53 with its regulators. p53 up-regulates its destabilizer Mdm2 and
down-regulates its activator p14ARF (18). In theory at least, the
observed NB phenotype could be explained by constitutive overexpression
or hyperactivity of p14ARF. However, p14ARF abnormalities in
neuroblastoma have not been reported. Also, if this were the case,
marked overexpression of Mdm2 in stable NB clones (Fig. 2D)
should have overcome the p53 resistance to degradation.
Interestingly, we had no difficulties in generating stable wild type
Mdm2 overexpressing neuroblastoma clones. This is in contrast to MCF-7
and U2OS cells, which do not tolerate stable overexpression of wild
type Mdm2 (15), consistent with cell cycle arrest activities of the
acidic domain of Mdm2 (49). Our experience suggests that this arrest
ability of Mdm2 is cell type-dependent and that its absence
might be linked to the p53 dysfunction present in NB cells. Cytoplasmic
sequestration of p53 is the hallmark of its hyperactive nuclear export
and prompted the original observation of this phenotype (21, 22). Yet,
there is no a priori reason for p53 to accumulate in the
cytoplasm, because its function might equally well be inactivated if
p53 were immediately degraded after its export. This reasoning suggests
a link between the two phenomena. p53 might be unable to lock itself
efficiently into the nucleus in response to stress because of an
aberrant modification that also prevents its efficient degradation by
Mdm2. Interestingly, high levels of ectopic p53 (Fig. 3, lanes
2), which localized mainly to the nucleus, had either nil or only
minimal activity in inducing transcriptional targets, as demonstrated
by the lack of response of the endogenous Mdm2 gene (Fig. 3,
A and B, compare lanes 1 and
2). Furthermore, endogenous and exogenous p53 in NB cells
completely failed to induce apoptosis after DNA
damage.2 These data further
confirm the profound impairment of p53 function in NB cells. Taken
together, the data suggest that hyperactive export of p53 in cells with
a cytoplasmic phenotype is one of two mechanisms of p53 inactivation.
The second mechanism is a functional block in the p53 signaling
pathway, either on the level of p53 or downstream.
In summary, our results show the importance of proper posttranslational
modification of the p53 protein in enabling high p53 turnover in
resting cells. This level of regulation is distinct from the known
structural requirements of the Mdm2 interaction site on the N terminus
of p53 and additional C-terminal domains on both proteins.
Interestingly, phosphorylation of the N or C terminus of p53 is not
absolutely required for stress signal-induced stabilization of p53
(50). Conversely, aberrant p53 modification is clearly able to prevent
Mdm2-mediated degradation in the absence of stress signals as shown
here. Resistance to other regulators of p53 stability such as JNK may
also play a role in NB cells (51). A full understanding of structural
and regulatory requirements of Mdm2-mediated p53 destruction is
critical, given the growing efforts in developing cancer agents
directed at stabilizing wild type p53 through Mdm2 targeting, thereby
activating p53 function (6, 52). Phenotypes with constitutive p53
accumulation, be it cytoplasmic or nuclear, will be valuable systems in
elucidating important mechanisms that regulate p53 turnover.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (23K):
[in a new window]
Fig. 1.
Abnormal p53 stability in neuroblastoma cells
is not due to a deficiency of Mdm2, lack of p53-Mdm2 interaction, or
lack of p53 ubiquitination. A, Mdm2 protein levels in
NB cells are within normal range. NB cell lines were compared with a
broad array of other cell lines. These fall into 4 categories of p53
steady state levels including p53-deficient cells (SaOs-2), low levels
of functional p53 (HT 1080 and IMR 90), mildly elevated levels of
functional p53 (RKO), and markedly increased levels of mutant p53 due
to a failure to induce Mdm2 (MDA 231 and 468). Lysates (100 mg) were
subjected to immunoblot analysis with anti-Mdm2 (IF2). DM cells are
mouse 3T3 fibroblasts with amplification of the Mdm2 gene and are shown
for comparison. B, Mdm2 interacts with p53. Lysates (1 mg)
of LAN-5 and IMR 90 cells were subjected to immunoprecipitation with
anti-Mdm2 (IF2) or mouse IgG (1.5 mg each) and co-precipitated p53 was
detected with CM-1. Loading of the blot was normalized for equal
intensities of p53 bands between the two cell lines. C, Mdm2
in NB cells retains its ability to enter into complexes with a major
physiologic partner, p14ARF. Clone HDM2-2 (see Fig. 2D) was
transiently transfected with a Myc-p14ARF expression plasmid. Lysates
(1 mg) were immunoprecipitated (IP) with 2 µg of anti-Myc
or mouse IgG and immunoblotted with anti-Mdm2. Lane W
represents an immunoblot only. D, p53 is properly
ubiquitinated. Lysates (50 or 100 µg) from LAN-5 and ML-1 cells
grown in the absence (
) of presence (+) of proteasome inhibitor MG
101 (50 mM) for 5 h were subjected to immunoblot
analysis with anti-p53 DO-1 and anti-lamin A (loading control).
E, neuroblastoma cells have a functional
ubiquitin-proteasome pathway. Steady state levels of IkBa in NB cell
lines are comparable to those from a broad range of non-NB tumor lines.
Shown is an immunoblot (100 µg of lysates) with anti-IkBa and
anti-actin as loading control.

View larger version (35K):
[in a new window]
Fig. 2.
Endogenous p53 is resistant to exogenous Mdm2
in NB cells. SaOs2 (A), LAN-5 (B), and
SK-N-SH (C) cells were transiently transfected with either
wild type Mdm2 (HDM2), nuclear export mutant Mdm2 (mutant nuclear
export signal (mtNES)), p53-contact mutant Mdm2 (G58A) or
empty vector (vect). p53-deficient SaOs2 control cells were
also co-transfected with wild type p53. GFP was co-transfected in all
cases to normalize the expression. D, a series of stable
LAN-5 subclones that overexpress either empty vector, wild type Mdm2
(HDM2 clones), or p53-contact mutant Mdm2 (G58A clones). Lysates were
subjected to immunoblot analysis with anti-Mdm2 (IF2), anti-p53 (DO-1),
anti-GFP, and anti-vimentin (loading control).

View larger version (39K):
[in a new window]
Fig. 3.
Exogenous p53 is equally resistant to
exogenous Mdm2 in NB cells. SK-N-SH (A) and LAN-5
(B) cells were transiently transfected with FLAG-wild type
p53 fusion protein (lanes 2-4), and either empty vector,
wild type Mdm2 (HDM2), or contact mutant Mdm2 (G58A). Lane 1 contains empty vector (vect) only. GFP was co-transfected in
all cases to normalize the expression. Lysates were subjected to
immunoblot analysis with anti-Mdm2, anti-FLAG, and anti-GFP.

View larger version (39K):
[in a new window]
Fig. 4.
p53 resistance toward Mdm2-directed
degradation is associated with covalent modification of p53.
A, left panel, one-dimensional immune isoelectric
focusing (IEF) of lysates from SK-N-SH (SH),
LAN-5, and MDA 231 breast carcinoma cells. Right lane
contains highly purified baculoviral human wild type p53 protein. The
pH gradient is indicated on the left. Right
panel, identical aliquots were immunoblotted to verify comparable
loading. Both panels were probed with anti-p53 (DO-1). B,
immunoprecipitation of p53 from small intestine (lane 2),
appendix (lane 3), colon (lane 4), two
undifferentiated neuroblastomas (lanes 5 and 6)
and LAN-5 (lane 7) with CM-1 followed by DO-1 blotting.
Lane 1 contains no lysate. C, the 421 epitope of
degradation-resistant p53 is masked independently of its subcellular
localization. LAN-5 cells were transiently transfected with p53
C-terminal peptides 305-360 and 320-360. These peptides span the
tetramerization domain and cause nuclear retention of endogenous p53
due to heterooligomerization and interference with hyperactive nuclear
export. Shown is the immunofluorescence of parental and transfectant
cells with PAB 1801 (left column) and 421 (right
column). Both antibodies are specific for endogenous p53. PAb 421 is a modification-sensitive antibody that recognizes its epitope (amino
acids 372-382) in the unmodified state. Whereas PAb 1801 recognizes
p53 in the cytoplasmic (parental) and nuclear (transfectant)
compartment of LAN-5 cells, PAb 421 gives no signal or only a minimal
signal. MDA 231 control cells are well recognized by 421. × 400.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
| |
ACKNOWLEDGEMENT |
|---|
We thank Dave Colflesh from University Microscopy Imaging Center (Stony Brook, NY) for imaging assistance.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grant R01 CA60664.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Pathology,
State University of New York at Stony Brook, Health Science Center,
Stony Brook, NY 11794. Tel.: 516-444-2459; Fax: 516-444-3424; E-mail: umoll@path.som.sunysb.edu.
2 A. Zaika and U. M. Moll, unpublished results.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: NB, neuroblastoma; GFP, green fluorescent protein; CBP, cAMP response element-binding protein.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997) Nature 387, 296-299[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Kubbutat, M. H., Jones, S. N., and Vousden, K. H. (1997) Nature 387, 299-303[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Shieh, S. Y., Ikeda, M., Taya, Y., and Prives, C. (1997) Cell 91, 325-334[CrossRef][Medline] [Order article via Infotrieve] |
| 4. |
Siliciano, J. D.,
Canman, C. E.,
Taya, Y.,
Sakaguchi, K.,
Appella, E.,
and Kastan, M. B.
(1997)
Genes Dev.
11,
3471-3481 |
| 5. |
Maltzman, W.,
and Czyzyk, L.
(1984)
Mol. Cell. Biol.
4,
1689-1694 |
| 6. | Böttger, A., Böttger, V., Sparks, A., Liu, W. L., Howard, S. F., and Lane, D. P. (1997) Curr. Biol. 7, 860-869[CrossRef][Medline] [Order article via Infotrieve] |
| 7. |
Maki, C. G.,
Huibregtse, J. M.,
and Howley, P. M.
(1996)
Cancer Res.
56,
2649-2654 |
| 8. | Freedman, D. A., Epstein, C. B., Roth, J. C., and Levine, A. J. (1997) Mol. Med. 3, 248-259[Medline] [Order article via Infotrieve] |
| 9. | Honda, R., Tanaka, H., and Yasuda, H. (1997) FEBS Lett. 420, 25-27[CrossRef][Medline] [Order article via Infotrieve] |
| 10. | Grossman, S. R., Perez, M., Kung, A. L., Joseph, M., Mansur, C., Xiao, Z. X., Kumar, S., Howley, P. M., and Livingston, D. M. (1998) Mol. Cell 2, 405-415[CrossRef][Medline] [Order article via Infotrieve] |
| 11. |
Kussie, P. H.,
Gorina, S.,
Marechal, V.,
Elenbaas, B.,
Moreau, J.,
Levine, A. J.,
and Pavletich, N. P.
(1996)
Science
274,
948-953 |
| 12. | Roth, J., Dobbelstein, M., Freedman, D. A., Shenk, T., and Levine, A. J. (1998) EMBO J. 17, 554-564[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Freedman, D. A.,
and Levine, A. J.
(1998)
Mol. Cell. Biol.
18,
7288-7293 |
| 14. |
Tao, W.,
and Levine, A. J.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
3077-3080 |
| 15. |
Kubbutat, M. H.,
Ludwig, R. L.,
Levine, A. J.,
and Vousden, K. H.
(1999)
Cell Growth Differ.
10,
87-92 |
| 16. |
Kamijo, T.,
Weber, J. D.,
Zambetti, G.,
Zindy, F.,
Roussel, M. F.,
and Sherr, C. J.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
8292-8297 |
| 17. | Pomerantz, J., Schreiber-Agus, N., Liegeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H. W., Cordon-Cardo, C., and DePinho, R. A. (1998) Cell 92, 713-723[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | Stott, F. J., Bates, S., James, M. C., McConnell, B. B., Starborg, M., Brookes, S., Palmero, I., Ryan, K., Hara, E., Vousden, K. H., and Peters, G. (1998) EMBO J. 17, 5001-5014[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Honda, R., and Yasuda, H. (1999) EMBO J. 18, 22-27[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
Kubbutat, M. H.,
Ludwig, R. L.,
Ashcroft, M.,
and Vousden, K. H.
(1998)
Mol. Cell. Biol.
18,
5690-5698 |
| 21. |
Moll, U. M.,
LaQuaglia, M.,
Benard, J.,
and Riou, G.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
4407-4411 |
| 22. |
Moll, U. M.,
Riou, G.,
and Levine, A. J.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
7262-7266 |
| 23. | Stenmark-Askmalm, M., Stal, O., Sullivan, S., Ferraud, L., Sun, X. F., Carstensen, J., and Nordenskjold, B. (1994) Eur. J. Cancer 30A, 175-180[CrossRef] |
| 24. | Lou, M. A., Tseng, S. L., Chang, S. F., Yue, C. T., Chang, B. L., Chou, C. H., Yang, S. L., Teh, B. H., Wu, C. W., and Shen, C. Y. (1997) Br. J. Cancer 75, 746-751[Medline] [Order article via Infotrieve] |
| 25. | Sun, X. F., Carstensen, J. M., Zhang, H., Stal, O., Wingren, S., Hatschek, T., and Nordenskjold, B. (1992) Lancet 340, 1369-1373[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Sun, X. F., Carstensen, J. M., Zhang, H., Arbman, G., and Nordenskjold, B. (1996) Eur. J. Cancer 32A, 963-1967 |
| 27. | Bosari, S., Viale, G., Roncalli, M., Graziani, D., Borsani, G., Lee, A. K., and Coggi, G. (1995) Am. J. Pathol. 147, 790-798[Abstract] |
| 28. |
Schlamp, C. L.,
Poulsen, G. L.,
Norks, T. M.,
and Nickells, R. W.
(1997)
J. Natl. Cancer Inst.
89,
1530-1536 |
| 29. | Aladjem, M. I., Spike, B. T., Rodewald, L. W., Hope, T. J., Klemm, M., Jaenisch, R., and Wahl, G. M. (1998) Curr. Biol. 8, 145-155[CrossRef][Medline] [Order article via Infotrieve] |
| 30. | Davidoff, A. M., Pence, J. C., Shorter, N. A., Iglehart, J. D., and Marks, J. R. (1992) Oncogene 7, 127-133[Medline] [Order article via Infotrieve] |
| 31. | Moll, U. M., Ostermeyer, A. G., Haladay, R., Winkfield, B., Frazier, M., and Zambetti, G. (1996) Mol. Cell. Biol. 16, 1126-1137[Abstract] |
| 32. | Isaacs, J. S., Hardman, R., Carman, T. A., Barrett, J. C., and Weissman, B. E. (1998) Cell Growth Differ. 9, 545-555[Abstract] |
| 33. | Stommel, J. M., Marchenko, N. D., Jimenez, G. S., Moll, U. M., Hope, T. J., and Wahl, G. M. (1999) EMBO J. 18, 1660-1672[CrossRef][Medline] [Order article via Infotrieve] |
| 34. | Fakharzadeh, S. S., Trusko, S. P., and George, D. L. (1991) EMBO J. 10, 1565-1569[Medline] [Order article via Infotrieve] |
| 35. |
Baker, S. J.,
Markowitz, S.,
Fearon, E. R.,
Willson, J. K. V.,
and Vogelstein, B. V.
(1990)
Science
249,
912-915 |
| 36. | Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., and Vogelstein, B. (1993) Nature 362, 857-860[CrossRef][Medline] [Order article via Infotrieve] |
| 37. | Zhang, Y., Xiong, Y., and Yarbrough, W. G. (1998) Cell 92, 725-734[CrossRef][Medline] [Order article via Infotrieve] |
| 38. | Copeland, R. A. (1994) Methods for Protein Analysis. A Practical Guide to Laboratory Protocols , Chapman & Hall, New York |
| 39. | Laney, J. D., and Hochstrasser, M. (1999) Cell 97, 427-430[CrossRef][Medline] [Order article via Infotrieve] |
| 40. | Chang, Y. C., Lee, Y. S., Tejima, T., Tanaka, K., Omura, S., Heintz, N. H., Mitsui, Y., and Magae, J. (1998) Cell Growth Differ. 9, 79-84[Abstract] |
| 41. | Patterson, R. M., He, C., Selkirk, J. K., and Merrick, B. A. (1996) Arch. Biochem. Biophys. 330s, 71-79[CrossRef][Medline] [Order article via Infotrieve] |
| 42. |
Fontoura, B. M.,
Sorokina, E. A.,
David, E.,
and Carroll, R. B.
(1992)
Mol. Cell. Biol.
12,
5145-5151 |
| 43. | Shaw, P., Freeman, J., Bovey, R., and Iggo, R. (1996) Oncogene 12, 921-930[Medline] [Order article via Infotrieve] |
| 44. |
Takenaka, I.,
Morin, F.,
Seizinger, B. R.,
and Kley, N.
(1995)
J. Biol. Chem.
270,
5405-5411 |
| 45. | Ullrich, S. J., Mercer, W. E., and Appella, E. (1992) Oncogene 7, 1635-1643[Medline] [Order article via Infotrieve] |
| 46. | Gu, W., and Roeder, R. G. (1997) Cell 90, 595-606[CrossRef][Medline] [Order article via Infotrieve] |
| 47. |
Ostermeyer, A.,
Runko, E.,
Winkfield, B.,
Ahn, B.,
and Moll, U. M.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
15190-15194 |
| 48. | Prives, C. (1998) Cell 95, 5-8[CrossRef][Medline] [Order article via Infotrieve] |
| 49. | Brown, D. R., Thomas, C. A., and Deb, S. P. (1998) EMBO J. 17, 2513-2525[CrossRef][Medline] [Order article via Infotrieve] |
| 50. |
Ashcroft, M.,
Kubbutat, M. H.,
and Vousden, K. H.
(1999)
Mol. Cell. Biol.
19,
1751-1758 |
| 51. |
Fuchs, S. Y.,
Adler, V.,
Buschmann, T.,
Yin, Z.,
Wu, X.,
Jones, S. N.,
and Ronai, Z.
(1998)
Genes Dev.
12,
2658-2663 |
| 52. |
Chen, L.,
Agrawal, S.,
Zhou, W.,
Zhang, R.,
and Chen, J.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
195-200 |
This article has been cited by other articles:
![]() |
S. Bottger, E. Jerszyk, B. Low, and C. Walker Genotoxic Stress-Induced Expression of p53 and Apoptosis in Leukemic Clam Hemocytes with Cytoplasmically Sequestered p53 Cancer Res., February 1, 2008; 68(3): 777 - 782. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Cohen, A. Meisser, L. Haenggeli, I. Irminger-Finger, and P. Bischof Status of p53 in first-trimester cytotrophoblastic cells Mol. Hum. Reprod., February 1, 2007; 13(2): 111 - 116. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Wichroski, K. Ichiyama, and T. M. Rana Analysis of HIV-1 Viral Infectivity Factor-mediated Proteasome-dependent Depletion of APOBEC3G: CORRELATING FUNCTION AND SUBCELLULAR LOCALIZATION J. Biol. Chem., March 4, 2005; 280(9): 8387 - 8396. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Rorie and B. E. Weissman The Ews/Fli-1 Fusion Gene Changes the Status of p53 in Neuroblastoma Tumor Cell Lines Cancer Res., October 15, 2004; 64(20): 7288 - 7295. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. SENGUPTA and B. WASYLYK Physiological and Pathological Consequences of the Interactions of the p53 Tumor Suppressor with the Glucocorticoid, Androgen, and Estrogen Receptors Ann. N.Y. Acad. Sci., June 1, 2004; 1024(1): 54 - 71. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Takemoto, Y. Mori, K. Ueda, K. Kondo, and K. Yamanishi Productive human herpesvirus 6 infection causes aberrant accumulation of p53 and prevents apoptosis J. Gen. Virol., April 1, 2004; 85(4): 869 - 879. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. M. Moll and O. Petrenko The MDM2-p53 Interaction Mol. Cancer Res., December 1, 2003; 1(14): 1001 - 1008. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Deb Cell Cycle Regulatory Functions of the Human Oncoprotein MDM2 Mol. Cancer Res., December 1, 2003; 1(14): 1009 - 1016. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. K. Kinyamu and T. K. Archer Estrogen Receptor-Dependent Proteasomal Degradation of the Glucocorticoid Receptor Is Coupled to an Increase in Mdm2 Protein Expression Mol. Cell. Biol., August 15, 2003; 23(16): 5867 - 5881. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. I. Zhou, H. Wang, J. J. Ross, I. Kuzmin, C. Xu, and H. T. Cohen The von Hippel-Lindau Tumor Suppressor Stabilizes Novel Plant Homeodomain Protein Jade-1 J. Biol. Chem., October 11, 2002; 277(42): 39887 - 39898. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Inoue, J. Stuart, R. Leno, and C. G. Maki Nuclear Import and Export Signals in Control of the p53-related Protein p73 J. Biol. Chem., April 19, 2002; 277(17): 15053 - 15060. [Abstract] [Full Text] [PDF] |
||||
![]() |
P A Hall, A C Woodman, S J Campbell, and N A Shepherd Expression of the p53 homologue p63{alpha} and {Delta}Np63{alpha} in the neoplastic sequence of Barrett's oesophagus: correlation with morphology and p53 protein Gut, November 1, 2001; 49(5): 618 - 623. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sengupta and B. Wasylyk Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2 Genes & Dev., September 15, 2001; 15(18): 2367 - 2380. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Chen, K. Aldape, J. K. Wiencke, K. T. Kelsey, R. Miike, R. L. Davis, J. Liu, A. Kesler-Diaz, M. Takahashi, and M. Wrensch Ethnicity Delineates Different Genetic Pathways in Malignant Glioma Cancer Res., May 1, 2001; 61(10): 3949 - 3954. [Abstract] [Full Text] |
||||
![]() |
W Ding, S Gao, and R. Scott Senescence represses the nuclear localization of the serum response factor and differentiation regulates its nuclear localiz |